DYADIC INTERNATIONAL, INC.

DYAI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-7.4M $-5.8M $-6.8M $-9.7M $-13.1M $-9.3M $-8.3M $-5.7M
Depreciation & Amortization
Depreciation
Amortization
Stock-Based Compensation $930.2K $1.1M $1.2M $1.9M $1.8M $1.7M $1.2M $467.2K
Net Cash from Operating Activities $-5.7M $-4.0M $-6.7M $-8.1M $-11.3M $-6.6M $-5.8M $-4.4M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities $82.1K $-1.9M $7.4M $-2.4M $5.2M $22.1M $7.7M $3.3M
Financing Activities
Dividends Paid
Stock Repurchases $0 $2.3M
Net Cash from Financing Activities $5.0M $5.8M $0 $543.6K $1.2M $255.5K $550.2K $-2.3M
Net Change in Cash $-653.3K $-8.3K $720.8K $-10.0M $-4.9M $15.8M $2.4M $-3.4M
Free Cash Flow
← Newer Page 1 of 2 Older →